ClinicalTrials.gg
Not yet recruitingNCT07845162Updated Sep 28, 2026

Serum EBI-3 Protein Levels in Behçet's Disease

An observational study in Behçet Disease, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Assiut University · Observational

How we know

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
90
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Behcet Syndrome by Assiut University — 6 open to participants now, 6 under way, none of them phase 3. Behcet Syndrome · Assiut University.

Planned enrollment
Largest of 14
90 · median 77
Started
2026
with 2 others
Observational
14 of 18
6 open now
Registered
18th of 18
by date

Among the 18 studies in Behcet Syndrome by Assiut University, this one has the largest planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2026, is one of 14 observational ones, and was the 18th registered.

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.

Browse Behcet Syndrome studies →

Open to participants now

6 of the 18 studies in Behcet Syndrome by Assiut University are open now. Recruiting first, the newest first:

All 6 open studies →

Where they have run

Who these studies take

Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Behcet Syndrome by Assiut University, or all of them as a file.
02

Study summary

This cross-sectional study aims to evaluate serum Epstein-Barr virus-induced gene 3 (EBI-3) protein levels in patients with Behçet's disease compared with healthy controls.

Read the detailed description

Behçet's disease is a chronic multisystem inflammatory disorder. Serum EBI-3 protein levels may reflect inflammatory activity.

This observational study will include adult patients diagnosed with Behçet's disease according to the International Criteria for Behçet's Disease and age-matched healthy controls. Serum EBI-3 protein levels will be measured by ELISA.

03

Conditions studied

  • Behçet Disease

Browse trials for

Keywords

  • Behçet's disease
  • EBI-3 Serum
  • biomarker
  • Assiut
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult patients with Behçet's disease attending the Physical Medicine, Rheumatology and Rehabilitation Department at Assiut University Hospitals, and healthy controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Age 18 years or older
  • Diagnosis of Behçet's disease according to the International Criteria for Behçet's Disease (cases)
  • Healthy individuals without or inflammatory diseases (controls)
  • Written

Exclusion criteria

Exclusion Criteria:

  • - Other disorders (RA, SLE, psoriatic arthritis, ankylosing spondylitis)
  • Acute or chronic infection
  • or history of malignancy
  • Chronic liver disease or advanced chronic kidney disease
  • Pregnancy or lactation
  • Vasculitis caused by diseases other than Behçet's disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Behçet's Disease

    Patients diagnosed with Behçet's disease according to the International Criteria for Behçet's Disease.

  • Healthy Controls

    Age-matched healthy individuals without autoimmune or inflammatory diseases.

06

What researchers measure

Primary outcomes

  1. Mean serum EBI-3 protein level

    Mean serum Epstein-Barr virus-induced gene 3 (EBI-3) protein concentration measured by ELISA in patients with Behçet's disease compared with healthy controls.

    Time frame: Baseline

Secondary outcomes

  1. Serum EBI-3 level according to disease activity

    Mean serum EBI-3 protein concentration according to Behçet's Disease Current Activity Form (BDCAF) score.

    Time frame: Baseline

  2. Serum EBI-3 level in patients with vascular involvement

    Mean serum EBI-3 protein concentration in patients with and without vascular involvement

    Time frame: Baseline

  3. Serum EBI-3 level in patients with ocular involvement

    Mean serum EBI-3 protein concentration in patients with and without ocular involvement.

    Time frame: Baseline

  4. Serum EBI-3 level in patients with neurological involvement

    Mean serum EBI-3 protein concentration in patients with and without neurological involvement.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartEst.
Sep 26, 2026
Primary completionEst.
Sep 26, 2027
CompletionEst.
Jan 25, 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07845162
Lead sponsor
Assiut University
Responsible party
Shrouk Samir Mohamed (Resident Physician, Department of Physical Medicine, Rheumatology and Rehabilitation, Assiut University) — Principal investigator
First posted
Sep 28, 2026
Start date
Sep 26, 2026 (estimated)
Primary completion
Sep 26, 2027 (estimated)
Completion
Jan 25, 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Shrouk S Mohamed, Resident
Contact
shrouk.18313202@med.aun.edu.eg
01004638754
Gehan I Abdelraziq, prof
study chair · Physical Medicine, Rheumatology and Rehabilitation Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion